Page 22

Abril_2107

ARTÍCULO DE INVESTIGACIÓN 430 Subclasificación molecular del cáncer colorrectal - A. M. Wielandt et al notype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006; 38 (7): 787-93. 27. Hurtado C, Wielandt AM, Zárate AJ, Kronberg U, Castro M, Yamagiwa K, et al. Molecular analysis of sporadic colon cáncer. Rev Med Chile 2015; 143 (3): 310-9. 28. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New- York: Springer; 2010. 29. Greene FL. Current TNM staging of colorectal cancer. Lancet Oncol 2007; 8 (7): 572-3. 30. Hardy RG, Meltzar SJ, Jankowski JA, ABC of Colorectal Cancer: Molecular basis for risk factors BJM 2000; 321: 886-9. 31. Zlobec I, Kovac M, Erzberger P, Molinari F, Bihl MP, Rufle A, et al. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer. Int J Cancer 2010; 127 (11): 2569-75. 32. Fessler E, Jansen M, De Sousa F, Melo E, Zhao L, Prasetyanti PR, et al. A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype. Oncogene 2016; 35: 6026-37. 33. Punt C, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol 2017;14 (4): 235-46. 34. B lanco-Calvo M, Concha Á Figueroa A, Garrido F, Valladares-Ayerbes M. Colorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology Approach. Int J Mol Sci 2015; 16 (6): 13610-32. 35. Müller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch 2016; 469 (2): 125-34. 36. De Sousa E, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013; 19 (5): 614- 8. 37. Zárate AJ, Álvarez K, Villarroel C, Wielandt AM, Kronberg U, Cavada G, et al. Caracterización del infiltrado linfocitario (cd3, cd4, cd8, cd45ro y foxp3) e inestabilidad microsatelital en pacientes con cáncer colorrectal. Rev Chil Cir 2015; 67 (1): 43-50. 38. Dunne PD, O’Reilly PG, Coleman HG, Gray RT, Longley DB, Johnston PG, et al. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer. Oncotarget 2016; 7 (24): 36632-44. 39. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency N Engl J Med 2015; 372: 2509-20. 40. Becht E, de Reyniès A, Giraldo NA, Pilati C, Buttard B, Lacroix L, et al. Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clin Cancer Res 2016; 22 (16): 4057-66. 41. Fessler E, Drost J, van Hooff SR, Linnekamp JF, Wang X, Jansen M, et al. TGFβ signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol Med 2016; 8 (7): 745-60. Rev Med Chile 2017; 145: 419-430


Abril_2107
To see the actual publication please follow the link above